TL;DR
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
A retrospective analysis of University of Florida health records found that glucosamine use was associated with a 25% higher likelihood of mild cognitive impairment progressing to dementia. The study also reported an association with higher mortality among people already diagnosed with Alzheimer’s disease and related dementias. The findings are preliminary and do not establish that glucosamine causes either outcome.
Glucosamine use was associated with a greater likelihood of mild cognitive impairment progressing to dementia in a retrospective analysis of University of Florida health records, researchers reported in a study published in Nature Metabolism. The finding raises a question about a widely used joint supplement, but does not show that glucosamine causes dementia to progress.
Researchers used deidentified records from UF Health covering 2012 to 2024 and focused on people diagnosed with Alzheimer’s disease and related dementias, or mild cognitive impairment (MCI). MCI involves measurable problems with memory or thinking beyond what is expected with normal aging, but may not substantially disrupt daily life. About 8% of patients in each group reported glucosamine use: 1,896 people with ADRD and 2,750 with MCI.
After accounting for age, sex and demographics, glucosamine use was associated with a 25% higher likelihood of MCI progressing to dementia. Among people already diagnosed with ADRD, use was also associated with a 25% higher mortality risk during a defined period. The researchers did not observe that mortality association in the MCI group. The source report does not specify the length of the mortality period, so the figures should not be read as absolute risks or as a comparison across a stated number of years.
The team also examined human brain tissue and mouse models and identified a possible metabolic pathway for further study. The report describes a process in which sugar structures are attached to proteins. Researchers found signs that this pathway may be excessively active in Alzheimer’s disease, and that glucosamine can enter related biochemical processes after crossing the blood-brain barrier. These experiments offer a possible biological explanation, but the report does not establish that this mechanism caused the patient-record associations.
A Common Supplement, a New Research Question
Glucosamine is sold over the counter and is commonly used by older adults for joint discomfort or joint health. An association involving a supplement used by many people could matter to patients, families and clinicians, especially when a person already has cognitive impairment. The study adds a potential safety question to research on Alzheimer’s disease, which has often centered on amyloid plaques and tau tangles.
The results do not answer whether people should start, stop or change their use of glucosamine. Because the research is observational, people who take the supplement may differ from those who do not in ways that also affect their health. The study’s senior author, Ramon Sun, said the findings add to evidence that altered metabolism may contribute to Alzheimer’s progression. That is a research interpretation, rather than proof that glucosamine worsens the disease.
The finding also points to a broader scientific question: whether metabolic changes in the brain could complement existing approaches focused on plaques and tangles. Sun said that addressing a metabolic defect could become a complement to those approaches. The study does not show that a treatment targeting this pathway works, or that changing glucosamine intake would alter a person’s disease course.
How Researchers Traced the Possible Link
The University of Florida team, working with researchers Yi Guo and Jiang Bian, applied artificial intelligence to deidentified patient records. The analysis covered records collected over 12 years, from 2012 through 2024. It compared reported glucosamine use with outcomes among patients diagnosed with MCI or ADRD. The researchers then used human brain tissue and mouse models to explore biological processes that might help explain the pattern.
Glucosamine is a naturally occurring, sugar-related molecule. Commercial supplements can be made from sources including shellfish shells or corn. According to the study report, the molecule can cross the blood-brain barrier and enter pathways involved in building complex sugar structures and attaching them to proteins. The researchers suggest that the effects may vary with the biological environment, meaning a healthy brain and an Alzheimer’s-affected brain might respond differently.
That proposed pathway sits alongside established areas of Alzheimer’s research. Plaques are deposits of amyloid beta between brain cells, while tangles are twisted forms of tau inside neurons. The UF researchers used spatial technology developed in Sun’s laboratory to map molecules in tissue and examine metabolic changes. The study’s emphasis on metabolism extends the research question; it does not replace or disprove research into plaques and tangles.
““While it’s an association and not proof of causality, it does raise an important clinical question that now deserves much more attention.””
— Matt Gentry, study co-author and chair of UF’s Department of Biochemistry and Molecular Biology
Cause, Risk and Patient Advice
Whether glucosamine itself causes faster progression remains unknown. Retrospective health-record studies can identify associations, but other differences between supplement users and nonusers may contribute. The analysis accounted for age, sex and demographics, but the supplied report does not describe every possible confounding factor or provide enough detail to judge how glucosamine use was measured over time.
The reported 25% figures are relative associations, not a statement that one in four users will develop dementia or die. The source does not give the baseline likelihoods needed to calculate absolute changes for an individual. It also does not provide the duration of the mortality follow-up in the supplied material. The mortality association appeared in the ADRD group, not the MCI group; the reason for that difference is not established.
The report characterizes the findings as preliminary and says they need testing in a human clinical trial. It does not provide trial results, prove that the proposed metabolic pathway explains the observed associations, or establish that stopping glucosamine would change outcomes. People making decisions about supplements and health conditions should consult a qualified health professional.
Clinical Trials Must Test the Finding
The next step identified by the researchers is testing the findings in a human clinical trial. Such research would be needed to examine whether glucosamine has a causal effect, clarify how the result varies by disease stage and assess outcomes over a defined period. The supplied report does not name a planned trial or provide a timeline for one.
Further work may also test the proposed metabolic pathway in Alzheimer’s disease and determine whether it could inform future treatment research. For now, the health-record analysis is a signal for investigation, rather than a basis for concluding that glucosamine is harmful or that changing its use will affect dementia progression.
Key Questions
Does this study prove glucosamine causes dementia to progress?
No. It found an association in a retrospective analysis of health records. That design cannot establish that glucosamine caused MCI to progress to dementia.
What outcomes were associated with glucosamine use?
After accounting for age, sex and demographics, researchers reported a 25% higher likelihood of MCI progressing to dementia among glucosamine users. They also reported a 25% higher mortality risk among people already diagnosed with ADRD, but not among the MCI group.
Should people stop taking glucosamine?
The study does not establish that stopping glucosamine changes dementia risk or progression. People considering changes to supplement use should discuss them with a qualified health professional.
What research comes next?
The researchers say the findings need testing in a human clinical trial. The supplied report does not identify a planned trial or its timing.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
